Bone Biologics Corp - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS

Ticker Exchange SIC # Website Latest Ticker
BBLG Nasdaq 3841 https://www.bonebiologics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Bone Biologics Corp

Bone Biologics Effects 1-for-30 Reverse Stock Split - Jun 6th, 2023 5:00 pm
BBLG: BBLG Has Solid Cash and Is Advancing Testing - May 16th, 2023 11:20 am
BBLG: Bone Biologics Announces the Approval of A Vital Trial - Apr 11th, 2023 12:27 pm
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia - Apr 11th, 2023 12:00 pm
BBLG: BBLG Provides Investment Opportunity Before Trials - Mar 17th, 2023 10:29 am
Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization - Jan 26th, 2023 1:30 pm
BBLG: A Potential Game-Changer for Back Surgeries - Nov 15th, 2022 11:10 am
Bone Biologics CEO Issues Letter to Stockholders - Oct 25th, 2022 12:00 pm
WallachBeth Capital Announces Closing of Bone Biologics $5,100,000 Underwritten Public Offering - Oct 13th, 2022 1:00 pm
Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering - Oct 12th, 2022 8:05 pm
CORRECTING and REPLACING Bone Biologics Prices $5,100,000 Underwritten Public Offering - Oct 7th, 2022 2:52 pm
WallachBeth Capital Announces Pricing of Bone Biologics $5,100,000 Underwritten Public Offering - Oct 7th, 2022 2:16 pm
BBLG: Market opportunity for Bone continues to grow. - Sep 15th, 2022 10:20 am
BBLG: Bone Biologics Set up For Success - Jun 7th, 2022 11:23 am